STOCKS TELEGRAPH

Author: ST Staff

  • Galectin Therapeutics, Inc. (GALT) Stock Surges Following Success of Topline Data from Belapectin Clinical Trial

    Galectin Therapeutics, Inc. (GALT) Stock Surges Following Success of Topline Data from Belapectin Clinical Trial

    Galectin Therapeutics, Inc. (GALT) stock prices were down by a marginal 1.43% as of the market closing on July 8th, 2021, bringing it down to USD$2.76. Subsequent premarket fluctuations have seen the stock skyrocket by 47.10%, bringing it up to USD$4.06.

    Positive Topline Data

    July 9th, 2021 saw the company report positive topline data from its Phase 1b Clinical Trial Extension of Belapectin in conjunction with KEYTRUDA in the treatment of advanced metastatic melanoma, as well as head and neck cancer. The combination immunotherapy showed a cancer control rate of 56% in melanoma patients and 40% in head and neck cancer.

    Details of the Study

    The melanoma patients enrolled in the study had exceptionally severe prognoses, with four out of nine patients reporting choroidal primary tumors and six out of nine having liver metastasis. The study found no toxicities that were deemed even possibly related to Belapectin. As per the findings from the Phase 1 study, the frequency and intensity of toxicities recorded with the combination were less than the expected toxicity with KEYTRUDA alone.

    Net Loss Reports

    The quarter ended March 31st, 2021 saw the company report USD$6.3 million in net loss applicable to common stockholders, representing a net loss of USD$0.11 per share. This is up from the USD$3.6 million in net loss reported in the same time period of the prior year, representing a net loss of USD$0.06 per share. The year-over-year difference was largely driven by increases in R&D expenses related to GALT’s NAVIGATE trial.

    R&D and G&A Expenses

    In accordance with costs associated with the NAVIGATE trial, research and development costs were up to USD$4.9 million for the 2021 quarter, up from the USD$2.1 million reported for the quarter ended March 31st, 2020. General and administrative costs for the quarter were reported at USD$1.4 million, the same as for the prior year quarter.

    Solid Liquidity Position

    The company reported USD$20.8 million in cash and cash equivalents as of March 31st, 2021, indicating a solid liquidity position. This was further consolidated by the receiving of USD$10 million in proceeds on April 16th, 2021 from an unsecured convertible promissory note from the Chairman of its Board of Directors.

    Future Outlook for GALT

    Armed with the massive success and promise of its clinical trial, GALT is poised to capitalize on the opportunities afforded to it in light of this recent development. The company is keen to leverage its stellar liquidity position in order to usher in sustained and significant growth over the long term.

  • Humanigen, Inc. (HGEN) Stock Trending Higher Following MHRA Acceptance of Lenzilumab Marketing Authorization Submission

    Humanigen, Inc. (HGEN) Stock Trending Higher Following MHRA Acceptance of Lenzilumab Marketing Authorization Submission

    Humanigen, Inc. (HGEN) stock prices were up by 1.96% as of the market closing on July 8th, 2021, bringing the price per share up to USD$16.65. Subsequent premarket fluctuations saw the stock rise by 17.24%, bringing it up to USD$19.52.

    Market Authorization Submission Accepted

    July 9th 2021 saw the company announce the acceptance of its Market Authorization submission of lenzilumab as a treatment for Covid-19, having begun in June 2021. The UK’s Medicine and Healthcare Products Regulatory Agency (MHRA) gave the green light for accelerated Covid-related rolling review, with the assessment expected to occur on a short timescale than a standard rolling review.

    Working Towards the Acceptance

    HGEN held various meetings with different UK authorities in the time leading up to the initiation of the submission for Marketing Authorization. This included, but was not limited to, a Rapid C-19 multiagency meeting with representatives from the MHRA, the Therapeutics Taskforce (TTF), the Dept. of Health and Social Care (DHSC), National Health Service England (NHSE), and the National Institute for Health and Care Excellence (NICE).

    Scope of Lenzilumab

    The proliferation of various strains of the coronavirus across the globe emphasize the continued need for effective treatments that can treat various strains for the millions that are still left unvaccinated. Despite an 86% first dose vaccination rate across the UK, current week-long hospitalization rates were nearly 2,500, a 45% increase over the prior period. Deaths in the UK resulting from Covid-19 were up to 161 over the prior week, a 40% increase from the numbers reported in the week before.

    Waiting Game

    The company continues to collaborate with its partners to situate themselves for the most effective distribution of lenzilumab, as they wait for the pending conditional approval of the use of the treatment in patients hospitalized because of Covid-19. With Market Authorization pending, HGEN is also waiting on Emergency Use Authorization in the United States. Should they be awarded concurrently, the company is preparing itself to ensure the appropriate allocation of the treatment in both the U.K and the U.S.

    Future Outlook for HGEN

    With the world hurtling towards global immunizations, HGEN is capitalizing on the available market space as newer variants of the coronavirus continue to devastate the globe. Current and potential investors are hopeful that the company will be able to leverage its resources to consolidate and expand its market footprint in order to usher in significant growth over the long term.

  • What Is Hurting The GBS Stock Premarket?

    What Is Hurting The GBS Stock Premarket?

    At last check in pre-market trading, shares of GBS Inc. (GBS) were down -3.31% at $3.80. Last session, GBS stock rose 33.2%, or $0.98, to $3.93. GBS stock fluctuated between a price range of $3.28 and $4.65. There were 8.28 million shares traded, exceeding GBS’ average daily volume over the past 50 days, which was 0.58 million, and the average volume for the year, which was 0.53 million.

    GBS’ stock has fallen -0.25% over the past week while it has fallen -48.63% over the past six months. During the last three months, GBS stock has declined by -29.32%, and since the beginning of the year it has lost -46.89%. GBS stock fell even after the company was awarded a $4.7 million grant by the Australian Federal Government.

    What was the purpose of the grant?

    GBS is a life science company that develops non-invasive, real-time monitoring and diagnostic tests that assist patients in monitoring and diagnosing medical conditions. Through its Biosensor Platform, GBS creates and launches diagnostic tests that people with diabetes urgently need to help them live a healthier life.

    A US$4.7 million, Australian Federal Government scientific grant has been awarded to GBS for the development of a biosensor manufacturing facility.

    • Under the Modern Manufacturing Strategy (MMS), the Government has identified this as one of six National Manufacturing Priorities.
    • Through the Australian Federal Government’s Modern Manufacturing Initiative, the Medical Products Priority Grant will support the establishment of an Australian medical device manufacturing facility that will scale up the production of the Printable Organic Electronic Biosensor technology for the Asia Pacific region.
    • Saliva Glucose Biosensors (SGB), GBS’s flagship product, will offer non-invasive blood glucose testing to people with diabetes by providing a non-invasive alternative to finger-stick glucose testing.
    • Through alternative testing methods, such as the use of an Organic Thin-Film Transistor (OTFT), the more than 460 million people who live with diabetes in the world can now determine their glucose level in real-time on an app or device.

    GBS’ COVID diagnostic plans:

    A rapid point-of-care diagnostic test called the SARS-CoV-2 Antibody Biosensor is also planned as an addition to the SGB and GBS intended to monitor exposure and immunity in real time in a bid to combat COVID-19. GBS is developing the SARS-CoV-2 Biosensor in collaboration with Harvard University’s Wyss Institute for Biologically Inspired Engineering. It is expected that GBS’ biosensor technology will integrate with the Institute’s eRapid electrochemical sensor technology to enable the detection of multiple SARS-CoV-2-related biomarkers simultaneously for point-of-care COVID-19 diagnostics.

  • Is There A Reason Why The RSLS Stock Is Expanding Premarket?

    Is There A Reason Why The RSLS Stock Is Expanding Premarket?

    At the last check, the share price of the premier physician-led weight loss and metabolic health solutions company, ReShape Lifesciences Inc. (RSLS) was up 17.68% at $5.99 in pre-market trading on Friday. At the end of the last trading session, ReShape’s stock closed at $5.09, gaining 23.84 %. Prices ranged between $3.85 and $5.15 for RSLS stock.

    RSLS stock traded 8.2 million shares, well above its average daily volume of 1.91 million shares over 100 days. Over the last five days, RSLS stock has gained 1.80%, while over the last month they have lost -49.20%. As a result of the company shifting its lead product manufacturing, RSLS stock has surged.

    How has RSLS transitioned manufacturing?

    As the nation’s leading company for weight loss and metabolic health, ReShape offers a complete line of proven products and services for the management of obesity and metabolic disease. In contrast to more invasive procedures such as gastric bypass or sleeve gastrectomy, the FDA-approved Lap-Band Program from RSLS offers its patients a minimally invasive, long-term treatment of obesity. Research (outside the U.S.) is being conducted with the ReShape Vest System, which mimics the gastric volume reduction effect of conventional weight-loss surgery by laparoscopically implanting a vest around the stomach.

    With it, obese or morbidly obese patients can lose weight rapidly without altering their anatomy permanently. Reshapecare is RSLS’s weight-management program that helps patients lose weight quickly and maintain their weight loss over time. RSLS recently launched its online marketplace ReShape Marketplace to bring consumers quality wellness products targeted at achieving better health.

    A Massachusetts manufacturer will now produce ReShape’s Lap-Bands after the company completed their transition from Apollo Endosurgery, Inc.

    • In addition, RSLS expects to benefit from this change by reducing costs, bettering margins, and controlling the manufacturing process directly.
    • A laparoscopic weight-loss device approved by the FDA specifically for people with BMIs of 30 or higher, the Lap-Band is now manufactured by RSLS.
    • Since 1993, over one million patients have undergone this procedure and most insurance companies reimburse eligible patients for it.
    • With 20 years of clinical evidence demonstrating lower complication and mortality rates than other surgical procedures, RSLS’ Lap-Band is proven to be the safest bariatric procedure available.

    What will RSLS gain from the current decision?

    ReShape (RSLS) will be in a better position to reduce cost and increase efficiency by bringing Lap-Band production under its direct operational control. RSLS has risen to meet the weight loss needs of a growing population and has also added manufacturing and logistics jobs to the United States since emerging from the recent pandemic.

  • MIND Technology, Inc. (MIND) Stock Exhibits Minor Volatility Ahead of Commencement of Dividends

    MIND Technology, Inc. (MIND) Stock Exhibits Minor Volatility Ahead of Commencement of Dividends

    MIND Technology, Inc. (MIND) stock prices were down by a marginal 1.54% as of the market closing on July 8th, 2021, bringing the price per share down to USD$1.92. Premarket fluctuations saw the stock rally by 4.69%, bringing it up to USD$2.01.

    Dividends Initiated

    July 6th 2021 saw the company announce the commencement of the paying of dividends on the company’s 9.00% Series A Preferred Stock, following the approval from the Board of Directors. The dividend will be in the amount of USD$0.5625 per share and will be paid on a quarterly basis for the period started May 1st, 2021, and ends July 31st, 2021. The dividend will be paid out to stockholders on record as of the close of the trading day on July 15th, 2021. The Series A Preferred Stock is listed on the Nasdaq under the ticker symbol MINDP.

    MIND’s Plan of Action

    The company is confident in its long-term outlook as it stays the course in regard to its strategic initiatives aimed at expanding the company’s product portfolio, as well as facilitating maximum market penetration. The company’s upcoming 5-year plan remains largely unchanged. The fourth quarter of fiscal 2021 saw the company expand its contract with a leading integrated geophysical company, PGS, that facilitated the provision of advanced source controller technology.

    Revenue Reports

    The first quarter of fiscal 2022, ended April 30th, 2021, saw the company report USD$4.2 million in revenues generated from the sale of Marine Technology Products. This is comparable to the USD$3.2 million reported in the prior-year quarter and USD$6.4 million in the previous quarter. As of the end of the quarter, the backlog of Marine Technology Products came in at USD$11 million, as compared to the USD$14.2 million reported as of January 31st, 2021.

    Net Loss

    Net loss arising from continuing of operations for the first quarter of fiscal 2022 came in at USD$3.7 million, as compared to the net loss of USD$3.3 million in the prior quarter and USD$6.4 million in the prior-year quarter. Net loss attributable to common shareholders was reported at USD$0.33 per share, as compared to a net loss of USD$0.30 per share for the fourth quarter of fiscal 2021 and a net loss of USD$0.59 per share for Q1 2021.

    Future Outlook for MIND

    With the company’s stock significantly more attractive to current and potential investors on account of the commencement of dividends, the company is poised to capitalize on the increase of its equity value. Shareholders are confident in the company’s ability to leverage the resources at their disposal to usher in long-term organic growth.

  • What Is Raising The ZOM Stock Up Pre Market?

    What Is Raising The ZOM Stock Up Pre Market?

    The shares of Zomedica Corp. (ZOM) have increased 4.51% to $0.7420 in premarket trading as of last check. Zomedica stock ended Thursday’s session down -3.43% at $0.71. There were 24.42 million shares traded which was below the average daily volume of 34.07 million shares during the past 50 days. Zomedica has a current market capitalization of $721.74 million, and its outstanding shares amount to 977.81 million. After providing an update on the company’s performance, ZOM stock has been rising.

    ZOM has updated what?

    Zomedica is a veterinary health company based in Ann Arbor, Michigan, that focuses on meeting the unmet needs of clinical veterinarians. ZOM intends to offer a product portfolio that emphasizes both patient and practitioner health by developing innovative diagnostics and medical devices. Zom is committed to helping veterinarians increase productivity and increase revenue while improving the care of animals.

    The veterinary health company, Zomedica, that designs point-of-care diagnostic products for both dogs and cats, has issued the following corporate update:

    • ZOM’s flagship product, TRUFORMA, will offer five initial assays to detect adrenal and thyroid disorders, followed by several more assays that will cover numerous diseases.
    • As of now, three of ZOM’s initial tests are available.
    • Since its development partner, Qorvo Biotechnologies, is yet to complete the fT4 and ACTH assays, ZOM wants to encourage veterinarians to adopt the TRUFORMA platform in order to test it.
    • ZOM is undertaking this effort now and will continue until the summer of 2021.
    • ZOM is also actively recruiting top-level representatives, professional services veterinarians, and support staff so that it can effectively execute its instrument placement programs and prepare for a significant increase in sales once fT4 and ACTH is available for purchase.
    • ZOM plans to hire fifteen direct sales representatives by the end of 2021, as well as four veterinarians who will perform professional services, as well as inside sales representatives and customer service personnel.
    • The fT4 assay is expected to hit the market in late September or early October, followed two months later by ACTH.
    • In addition, three new tests (cPL, Cobalamin, and Folate) are under development to diagnose gastro-intestinal conditions.

    ZOM’s further efforts:

    Currently, Ziomedica (ZOM) and Qorvo are discussing when and how further assays will be developed after those already identified. It is also expected that ZOM’s TRUFORMA will be available in select markets outside the United States in 2022. Zomedica employees in Michigan have also returned to working on-premises beginning July 6, 2021.

  • What Happened Afterhours To Make TrueCar Stock Jump?

    What Happened Afterhours To Make TrueCar Stock Jump?

    Yesterday, shares of the most efficient and transparent online destination to find a car, TrueCar Inc. (TRUE) traded at $5.97 at last check-in after-hours trading, up 9.34%. TrueCar’s shares ended the day at $5.46, up 0.37%. There were 1.07 million shares traded during the trading session, which is higher than TrueCar’s average volume of 958.24K shares over the last three months. TRUE stock fluctuated between $5.265 and $5.6588 during the trading session. The TRUE stock had a P/E ratio of -0.18.

    TRUE stock traded down -3.36% in the past week, recovered 2.06% in the last month, but has gained 30.00% on a cumulative basis. In the 50-day moving average of the TRUE stock, the price sits above $4.84 but below the 200-day moving average of $5.21. Furthermore, TRUE stock trades at a current RSI of 49.75. Price of TRUE stock rose on reports that new vehicle sales were projected to grow double-digits in June 2021.

    What forecasts has TrueCar made?

    Among the nation’s largest automotive digital marketplaces, TrueCar connects buyers and sellers with its nationwide network of Certified Dealers. In its quest to bring more of the purchasing process online, TrueCar aims to create the industry’s most personal and efficient car-buying experience. Those who visit TrueCar’s marketplace will find a variety of tools to help them discover new and used cars, plus a price rating system and market context that helps them understand what a good deal is.

    The TrueCar App will provide them with the ability to connect with a local Certified Dealer who embraces the belief that trust, accountability, and fairness are the building blocks of a great car buying experience. Santa Monica, California, is TrueCar’s headquarters, while Austin, Texas, is the company’s office.

    Yesterday, TrueCar forecast that its new vehicle sales will reach 1,287,536 units in June 2021, an increase of 16% year-over-year.

    When adjusted for the same number of sales days, however, the forecast was down 16% compared to May 2021. Compared to the seasonally adjusted annualized rate (SAAR) of 13.0 million in June 2020, TrueCar estimates total light vehicle sales this month at 15.2 million. For new cars and light trucks sold at US retail, TrueCar expects 1,133,299 vehicles, a 11% increase from May 2020 and 17% decrease from May 2021.

    Where does TrueCar go from here?

    TrueCar (TRUE) has been closely watching the decline in new car inventory since January, but sales have been strong until recently because of an abundance of demand. Despite increased growth compared to last year, TrueCar expects some softer gains in June compared to prior months. Further swaying shoppers to remain on the fence this month may be the sharp decline in incentives and an increase in transaction prices, which are both causing TrueCar’s inventory to decline.

  • What Drove The CLRB Stock Up In Extended Trading?

    What Drove The CLRB Stock Up In Extended Trading?

    After-hours trading on Thursday showed shares of Cellectar Biosciences Inc. (CLRB) increasing 4.50% to $1.16. In yesterday’s trading, the price of Cellectar stock fell by -1.77%, ending at $1.11 on the day. Trading volume for the CLRB stock was 1.95 million shares, below the average daily volume of 0.68 million shares for the last 50 days.

    Within the last five days, CLRB shares have lost -6.72%, but their price has dropped -26.97% over the last thirty days. CLRB share price has declined -27.92% over the last three months, while it has lost -27.45 percent for the year. After the company announced that its CEO would participate in an international healthcare conference, the price of CLRB stock rose.

    CLRB will be participating in what event?

    Cellectar focuses on discovering and developing drugs for treating cancer. In addition to developing proprietary drugs independently, CLRB collaborates with various research institutions. The main objective of CLRB is to leverage its proprietary Phospholipid Drug Conjugate (PDC) delivery platform to develop PDCs that target cancer cells specifically, delivering better efficacy and safer side effects due to fewer off-target effects. In order to discover and develop the next generation of cancer-targeting treatments, CLRB is developing its PDC platform independently as well as working with outside companies to achieve that goal.

    Cellectar announced that James Caruso, president, and CEO, will present a company overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference.

    A one-on-one meeting will also be possible with the CLRB CEO. CLRB head will present the company overview on July 14, 2021, at 3:00 pm ET. Live webcast of the presentation by CLRB CEO will also be available at https://wsw.com/webcast/ladenburg7/clrb/2395361. The CLRB website will have a replay of the presentation available under the Events section.

    Cellectar announced recently that Dr. Asher Alban Chanan-Khan has been elected an independent director on its board.

    • He will bring to CLRB a wealth of distinguished medical and scientific experience related to cancer, particularly in hematological cancers.
    • CLRB will benefit greatly from his insight and advice as it builds its pipeline of cancer-targeting assets and further optimizes its PLE-conjugate platform technology.
    • The CLR 131 and the phospholipid ether delivery vehicle offered by CLRB have high potential and great opportunities.

    How the addition will help CLRB move forward?

    Cellectar (CLRB) recently presented data on CLR 131 at ASCO in which the clinical benefits of this novel, fixed duration treatment for Waldenstrom’s disease were clearly demonstrated. CLRB has appointed Dr. Asher to work alongside its team of investigators as CLRB develops CLR 131 through clinical trials and demonstrates the technology’s considerable capability through further research.

  • Why The Sphere 3D Stock Fell In Extended Trades?

    Why The Sphere 3D Stock Fell In Extended Trades?

    The share price of Sphere 3D Corp. (ANY) fell -3.77% to $3.32 in after-hours trading on Thursday. Sphere 3D completed its last trading session at $3.45, up 18.97% on the day. ANY shares had a price range of $2.60 to $3.47. The volume of shares traded in ANY was 16.15 million, which was higher than its daily average of 4.43 million. Over the last five days, shares of ANY have gained 32.18%, while they have gained 90.61% during the past month.  In extended trading, ANY stock dropped after gaining value in regular trading.

    Why did ANY stock rise on the day?

    Sphere 3D helps customers reach their IT goals by supporting them from beginning to end. There are several brands in the portfolio of ANY, including UCX Connections and HVE Connections. ANY specializes in cloud computing and containerization solutions.

    Sphere 3D announced that its to be merged with company, Gryphon Digital has entered into a contractual agreement to purchase 7,200 Antminer S19J Pro miners for an aggregate purchase price of $48 million from Bitmain Technologies Limited.

    • Gryphon’s agreement to buy the S19J Pro miners represents a significant step forward in its effort to cultivate a zero-emission mining operation that increases Bitcoin hash rate.
    • Earlier this summer Bitmain announced the release of its S19J Pro model.
    • In addition to an industry-leading energy efficiency ratio of 29.5 J/TH, the new miner has an expected life cycle of over five years with a maximum hash rate of 100 TH/s together.
    • Bitmain plans on delivering 600 miners per month to Gryphon beginning in August 2021.
    • With the completion of this purchase agreement, Gryphon will have access to a substantial amount of hashing power.
    • This will allow Gryphon’s fleet of high-efficiency miners to be part of the only cryptocurrency mining operation powered by 100% renewable energy.

    It has recently been announced that Sphere 3D has entered into a merger agreement with Gryphon, an independent company which mines bitcoin using renewable energy.

    • Sphere 3D (ANY) will be re-branded as Gryphon Digital Mining Inc. upon completion of the merger.
    • With the merger, Gryphon will expand its digital mining operations and leverage the proprietary enterprise solutions from Sphere 3D to optimize its operations.
    • Rob Chang, Chief Executive Officer of Gryphon, will serve as the combined company’s CEO following the merger.
    • Both companies’ boards of directors have approved the transaction.

    How the merger will be completed?

    If both companies’ stockholders approve the merger, and other closing conditions are met, Sphere 3D (ANY) anticipates closing the merger in the third quarter of 2021. The shareholders of Gryphon will receive 111,000,000 common shares of Sphere 3D upon the close of the Merger.

  • Why The NMTR Stock Fell Afterhours?

    Why The NMTR Stock Fell Afterhours?

    At last check in after-hours trading, shares of clinical-stage company focused on rare and unmet needs in gastroenterology  9 Meters Biopharma Inc. (NMTR) were down -3.23% at $1.20. Last session, 9 Meters closed at $1.24, up 20.39% or $0.21. During regular trading, the share price of NMTR fluctuated between $1.03 and $1.42.

    There were 43.89 million shares of NMTR stock exchanged, more than the daily volume of 5.11 million for the past 50 days and higher than the volume for the year to date. NMTR stock has fallen 101.36% in the past 12 months and has risen 12.73% in the last week. Over the past three months, NMTR shares have increased by 4.20%, and the stock has dropped by -9.49% during the last six months.

    NMTR stock rose during the regular session on news that it will participate in a biotech conference but has lost ground after hours.

    NMTR will participate in which event?

    9 Meters Biopharma is a gastroenterology company focused on rare and unmet needs. NMTR is developing vurolenatide, an orphan disease medicine, in a Phase 2 clinical trial for short bowel syndrome (SBS). Larazotide, another tight junction regulator, is also being evaluated by NMTR to improve symptoms of celiac disease.

    NMTR CEO John Temperato will participate in a virtual fireside chat at a health event, announced 9 Meters Biopharma.

    The NMTR CEO will take part in the William Blair Biotech Focus Conference on July 14-15, 2021. Investors are invited to join NMTR’s webcast live. John Temperato, Chief Executive Officer of 9 Meters Biopharma, will present at the William Blair Biotech Focus Conference on Thursday, July 15, 2021 at 12:00 to 2:45 p.m. Eastern Time.

    The presentation will be webcast live and may be accessed on the Investors page of the company’s website at https://wsw.com/webcast/blair59/nmtr/1964248, where a replay of the presentation will also be available for a 30-day period.

    Moreover, at the conclusion of the annual Russell US Index reconstitution, 9 Meters Biopharma was added to the Russell 3000 Index, a broad-market index, and the Russell 2000 Index, a small-cap index. As of the opening of the US equity markets on Monday June 28, 2021, these updated Indexes are in effect.

    The Russell indexes represent the 4,000 biggest US stocks based on their total market capitalization as of May 7, 2021. FTSE Russell determines membership for its Russell indexes primarily through objective rankings and criteria that are associated with market capitalization.

    What its addition to Russell means for NMTR?

    NMTR’s perseverance and accomplishments, including adding 9 Meters to the Russell Indexes, are indicative of its efforts to become a treatment leader in rare and unmet gastrointestinal disorders. By including 9 Meters Biopharma (NMTR) in the Russell Indexes, the company will raise its visibility when it is nearing several key milestones.